Search
DYN-101
go.drugbank.com/drugs/DB17921InvestigationalDYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.
CTX110
go.drugbank.com/drugs/DB18626InvestigationalCTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
REM-422
go.drugbank.com/drugs/DB19304InvestigationalREM-422 is an orally bioavailable, small molecule mRNA degrader of the proto-oncogene c-Myb.
177Lu-NI-FAPI
go.drugbank.com/drugs/DB33977Experimental177Lu-NI-FAPI is a small molecule drug. 177Lu-NI-FAPI is under investigation in clinical trial NCT07822347 (Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related
Bombesin
go.drugbank.com/drugs/DB11724InvestigationalBombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86
BT200
go.drugbank.com/drugs/DB18333Investigational[A261491] It is under investigation for the treatment of von Willebrand disease and hemophilia A.[L48156]
Biropepimut-S
go.drugbank.com/drugs/DB14816InvestigationalBiropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral
BBM-H901
go.drugbank.com/drugs/DB17704InvestigationalIt is being investigated for the treatment of hemophilia B.[A259048]
FB-101
go.drugbank.com/drugs/DB17956InvestigationalDeveloped by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]